Metabolism in cancer cells differs from that in normal cells, but it is only recently that opportunities to specifically target these differences to develop novel anticancer drugs are being revealed. Jim Schnabel investigates new collaborations to harness this potential.
This is a preview of subscription content
Access options
Subscribe to Journal
Get full journal access for 1 year
$59.00
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
Rights and permissions
About this article
Cite this article
Targeting tumour metabolism. Nat Rev Drug Discov 9, 503–504 (2010). https://doi.org/10.1038/nrd3215
Issue Date:
DOI: https://doi.org/10.1038/nrd3215
Further reading
-
ROS homeostasis and metabolism: a critical liaison for cancer therapy
Experimental & Molecular Medicine (2016)
-
Targeting tumour-supportive cellular machineries in anticancer drug development
Nature Reviews Drug Discovery (2014)
-
Synthesis, characterization, and biological studies of emissive rhenium–glutamine conjugates
JBIC Journal of Biological Inorganic Chemistry (2013)